MX2018007333A - Compuestos heteroaromaticos como inhibidores de btk. - Google Patents

Compuestos heteroaromaticos como inhibidores de btk.

Info

Publication number
MX2018007333A
MX2018007333A MX2018007333A MX2018007333A MX2018007333A MX 2018007333 A MX2018007333 A MX 2018007333A MX 2018007333 A MX2018007333 A MX 2018007333A MX 2018007333 A MX2018007333 A MX 2018007333A MX 2018007333 A MX2018007333 A MX 2018007333A
Authority
MX
Mexico
Prior art keywords
treatment
bipyrazolyl
autoimmune diseases
derivatives useful
compounds
Prior art date
Application number
MX2018007333A
Other languages
English (en)
Inventor
Martin Bentzien Joerg
Aaron Tschantz Matt
Bosanac Todd
Jason Burke Michael
Mao Wang
Shen Yue
Soleymanzadeh Fariba
Michael Fryer Ryan
Thomas Larson Eric
Patrick Mckibben Bryan
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2018007333A publication Critical patent/MX2018007333A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

La presente invención abarca los compuestos de la Fórmula (I) (ver Fórmula) en donde los grupos R1, Cy e Y se definen en la presente, que son adecuados para el tratamiento de enfermedades relacionadas con BTK, y los procesos para fabricar estos compuestos, las preparaciones farmacéuticas que contienen estos compuestos y sus métodos de uso.
MX2018007333A 2015-12-16 2016-12-15 Compuestos heteroaromaticos como inhibidores de btk. MX2018007333A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268278P 2015-12-16 2015-12-16
US201662431008P 2016-12-07 2016-12-07
PCT/US2016/066799 WO2017106429A2 (en) 2015-12-16 2016-12-15 Heteroaromatic compounds as btk inhibitors

Publications (1)

Publication Number Publication Date
MX2018007333A true MX2018007333A (es) 2018-08-24

Family

ID=58737849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007333A MX2018007333A (es) 2015-12-16 2016-12-15 Compuestos heteroaromaticos como inhibidores de btk.

Country Status (31)

Country Link
US (6) US9975882B2 (es)
EP (1) EP3390390B1 (es)
JP (1) JP6976947B2 (es)
KR (1) KR20180095655A (es)
CN (1) CN108368086B (es)
AU (1) AU2016370743B2 (es)
BR (1) BR112018011969B1 (es)
CA (1) CA3005268A1 (es)
CL (1) CL2018001569A1 (es)
CO (1) CO2018005954A2 (es)
CY (1) CY1124749T1 (es)
DK (1) DK3390390T3 (es)
EA (1) EA034561B1 (es)
ES (1) ES2897910T3 (es)
HK (1) HK1256795A1 (es)
HR (1) HRP20211845T1 (es)
HU (1) HUE056877T2 (es)
IL (1) IL259281B (es)
LT (1) LT3390390T (es)
MX (1) MX2018007333A (es)
MY (1) MY197440A (es)
PE (1) PE20181074A1 (es)
PH (1) PH12018501248A1 (es)
PL (1) PL3390390T3 (es)
PT (1) PT3390390T (es)
RS (1) RS62525B1 (es)
SA (1) SA518391864B1 (es)
SG (1) SG11201804890TA (es)
SI (1) SI3390390T1 (es)
TW (1) TWI726017B (es)
WO (1) WO2017106429A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015001802A (es) 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
CN108368086B (zh) * 2015-12-16 2021-01-08 勃林格殷格翰国际有限公司 可用于治疗自身免疫疾病的二吡唑基衍生物
PE20220502A1 (es) 2015-12-16 2022-04-07 Loxo Oncology Inc Compuestos utiles como inhibidores de cinasa
JP6916185B2 (ja) 2016-01-13 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのイソキノロン類
WO2019027860A1 (en) * 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh INTERMEDIATE COMPOUNDS AND METHODS
KR102545594B1 (ko) 2018-07-31 2023-06-21 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN113811301A (zh) * 2019-05-23 2021-12-17 诺华股份有限公司 使用布鲁顿酪氨酸激酶抑制剂治疗舍格伦综合征的方法
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
WO2001056993A2 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
WO2003015776A1 (en) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US7307097B2 (en) 2001-09-27 2007-12-11 Smithkline Beechman Corporation Chemical compounds
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
CA2648923A1 (en) 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
SI2530083T1 (sl) 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
ES2562215T3 (es) 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
PL2310528T3 (pl) 2008-07-29 2014-04-30 Univ Liege Marker genetyczny do testowania brachyspiny i płodności u bydła
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
JP2013514287A (ja) 2009-12-17 2013-04-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング スフィンゴシンキナーゼの阻害薬
NZ603643A (en) 2010-05-31 2014-07-25 Ono Pharmaceutical Co Purinone derivative
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9458162B2 (en) 2012-01-31 2016-10-04 Nanjing Allgen Pharma Co. Ltd. Cyclic molecules as bruton's tyrosine kinase inhibitors
MX2015001802A (es) 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
GEP201606597B (en) 2012-11-02 2017-01-10 Pfizer Bruton's tyrosine kinase inhibitors
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014151620A1 (en) * 2013-03-14 2014-09-25 Boehringer Ingelheim International Gmbh 5-thiazolecarboxamide dervatives and their use as btk inhibitors
JP6486954B2 (ja) 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのピラゾール化合物
CN108368086B (zh) * 2015-12-16 2021-01-08 勃林格殷格翰国际有限公司 可用于治疗自身免疫疾病的二吡唑基衍生物

Also Published As

Publication number Publication date
HUE056877T2 (hu) 2022-03-28
EA201891399A1 (ru) 2019-01-31
US20210009567A1 (en) 2021-01-14
DK3390390T3 (da) 2021-12-06
CN108368086B (zh) 2021-01-08
PT3390390T (pt) 2021-11-18
BR112018011969A2 (pt) 2018-12-04
ES2897910T3 (es) 2022-03-03
RS62525B1 (sr) 2021-11-30
CL2018001569A1 (es) 2018-10-05
US20170174663A1 (en) 2017-06-22
WO2017106429A3 (en) 2017-08-17
HRP20211845T1 (hr) 2022-03-04
HK1256795A1 (zh) 2019-10-04
US20180222893A1 (en) 2018-08-09
CY1124749T1 (el) 2022-07-22
SA518391864B1 (ar) 2021-12-13
LT3390390T (lt) 2021-11-25
SI3390390T1 (sl) 2021-12-31
IL259281B (en) 2021-04-29
TW201731838A (zh) 2017-09-16
BR112018011969B1 (pt) 2023-02-23
IL259281A (en) 2018-07-31
CO2018005954A2 (es) 2018-07-10
CN108368086A (zh) 2018-08-03
SG11201804890TA (en) 2018-07-30
JP2019505491A (ja) 2019-02-28
CA3005268A1 (en) 2017-06-22
EP3390390B1 (en) 2021-09-01
MY197440A (en) 2023-06-19
KR20180095655A (ko) 2018-08-27
PL3390390T3 (pl) 2022-01-24
PH12018501248A1 (en) 2019-01-28
AU2016370743A1 (en) 2018-05-24
TWI726017B (zh) 2021-05-01
WO2017106429A2 (en) 2017-06-22
US9975882B2 (en) 2018-05-22
US20180030037A1 (en) 2018-02-01
US20190092759A1 (en) 2019-03-28
EP3390390A2 (en) 2018-10-24
JP6976947B2 (ja) 2021-12-08
PE20181074A1 (es) 2018-07-04
EA034561B1 (ru) 2020-02-20
US20200055843A1 (en) 2020-02-20
AU2016370743B2 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
PH12018501248A1 (en) Biprazolyl derivatives useful for the treatment of autoimmune diseases
PH12020500252A1 (en) Compounds as modulators of ror gamma
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
TR201819138T4 (tr) FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
TW201613864A (en) Novel compounds
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2017007377A (es) Compuestos organicos.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PH12016501613A1 (en) Pyrazines modulators of gpr6
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX371158B (es) Compuestos inhibidores de pde2.

Legal Events

Date Code Title Description
FG Grant or registration